Actualités Ascencio Sca - ASCE | Actions Euronext

Outils de qualité professionnelle, pour des investisseurs individuels.

Assemblée générale extraordinaire du 5 juillet 2023 - Convocation

Assemblée générale extraordinaire du 5 juillet 2023 - Convocation Compte tenu du nombre d’actions pour lesquelles les actionnaires ont...

Déclaration de transparence - Notification

Déclaration de transparence - Notification Résumé Ascencio a reçu une notification de transparence de la part du Groupe AGEAS l’informant du...

Press Release - Half-Yearly Financial Report

Press Release - Half-Yearly Financial Report Half-yearly financial report of Ascencio SA - Results to 31 March 2023 ...

Extraordinary General Meeting of 16 Juny 2023

Extraordinary General Meeting of 16 Juny 2023 Dear Madam, Sir, Please find hereafter our press release regarding the extraordinary general...

Interim statement at 31/12/2022 - First quarter of financial year 2022-2023

Interim statement at 31/12/2022 - First quarter of financial year 2022-2023 Dear Madam, Sir, Please find hereafter our press release...

Extraordinary General Meeting of 17 February 2023

Extraordinary General Meeting of 17 February 2023 Dear Madam, Sir, Please find hereafter our press release regarding the Extraordinary...

Duncan Technology Group Completes Reverse Merger With Ascentia Biomedical Corporation

NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Ascentia Biomedical Corporation ("Ascentia") (OTC:ASCE) today announced that, effective November 28...

Ascentia Biomedical Announces a Shift to Biomedical Arbitrage and Development to Achieve Profitability

BELLEVUE, Wash., May 30 /PRNewswire-FirstCall/ -- Ascentia Biomedical Corporation (OTC Pink Sheets: ASCE), a leading researcher and developer of...

Ascentia Biomedical Corporation Announces the Addition of Dr. Philip Mease, an Internationally Recognized Rheumatologist, to the

BELLEVUE, Wash., Sept. 30 /PRNewswire-FirstCall/ -- Ascentia Biomedical Corporation (OTC Pink Sheets: ASCE), a leading researcher and developer...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ascencio Sca (ASCE)

Outils de qualité professionnelle, pour des investisseurs individuels.

ASCE Actualités

Assemblée générale extraordinaire du 5 juillet 2023 - Convocation

Déclaration de transparence - Notification

Press Release - Half-Yearly Financial Report

Extraordinary General Meeting of 16 Juny 2023

Interim statement at 31/12/2022 - First quarter of financial year 2022-2023

Extraordinary General Meeting of 17 February 2023

Duncan Technology Group Completes Reverse Merger With Ascentia Biomedical Corporation

Ascentia Biomedical Announces a Shift to Biomedical Arbitrage and Development to Achieve Profitability

Ascentia Biomedical Corporation Announces the Addition of Dr. Philip Mease, an Internationally Recognized Rheumatologist, to the

Ascentia Biomedical Receives $1 Million Funding Commitment to Support Continued Research and Organizational Growth

Ascentia Biomedical Corporation Further Defines Option Agreement With University of Washington for Anti-Cancer Compound

Ascentia Biomedical Corporation Announces Option Agreement With University of Washington for Anti-Cancer Compound

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ascencio Sca (ASCE) Actualités

Ascencio Sca (ASCE)

Outils de qualité professionnelle, pour des investisseurs individuels.

ASCE Actualités

Assemblée générale extraordinaire du 5 juillet 2023 - Convocation

Déclaration de transparence - Notification

Press Release - Half-Yearly Financial Report

Extraordinary General Meeting of 16 Juny 2023

Interim statement at 31/12/2022 - First quarter of financial year 2022-2023

Extraordinary General Meeting of 17 February 2023

Duncan Technology Group Completes Reverse Merger With Ascentia Biomedical Corporation

Ascentia Biomedical Announces a Shift to Biomedical Arbitrage and Development to Achieve Profitability

Ascentia Biomedical Corporation Announces the Addition of Dr. Philip Mease, an Internationally Recognized Rheumatologist, to the

Ascentia Biomedical Receives $1 Million Funding Commitment to Support Continued Research and Organizational Growth

Ascentia Biomedical Corporation Further Defines Option Agreement With University of Washington for Anti-Cancer Compound

Ascentia Biomedical Corporation Announces Option Agreement With University of Washington for Anti-Cancer Compound

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités